We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Amazon.com, Novo Nordisk, Qualcomm, Booking Holdings and Chubb
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 23, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Novo Nordisk A/S (NVO - Free Report) , Qualcomm Inc. (QCOM - Free Report) , Booking Holdings Inc. (BKNG - Free Report) and Chubb Ltd. (CB - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Amazon, Novo Nordisk and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Novo Nordisk A/S and Qualcomm Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Amazon.com lagged the broader market (-38.7% vs. -11.2% for the S&P 500) and the Zacks Tech sector (-14%) over the past year, reflecting fears of an extended period of post-Covid retrenchment in the company's capacity both in the retail as well as cloud businesses. Further, softness in online shopping activities remains a negative for its online stores.
These near-term challenges notwithstanding, Amazon's AWS business remains well positioned for the eventual recovery in business cloud spending. Ultrafast delivery services and expanding content portfolio effectively guarantee that Amazon hangs onto its market share in this period of weakness. Strengthening relationships with third-party sellers was a positive. Robust advertising business contributed well.
Improving Alexa skills along with robust smart home products offerings were tailwinds. Amazon's strong global presence and solid momentum among the small and medium businesses remain positives.
Novo Nordisk shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+34.7% vs. +2.9%). The company has one of the broadest diabetes portfolios in the industry. Ozempic and Rybelsus have been performing well in the market. Drug sales have been gaining and maintaining momentum.
Label expansion of the existing drugs is likely to further boost sales. Ozempic is off to a solid start since its launch and will drive growth for the company. The launch of Rybelsus also looks impressive.
The supply issues with Wegovy have been resolved. The company has been diversifying its efforts to develop new treatments, which is encouraging. The patent expiry on some of the products in Novo Nordisk's portfolio remains a woe.
Qualcomm shares have underperformed the Zacks Wireless Equipment industry over the past year (-19.0% vs. -15.5%). The company has offered a muted outlook for the second quarter due to rapid deterioration in demand and high channel inventory amid a challenging macroeconomic environment and business uncertainty.
Qualcomm expects softness in the handset market and weaker overall mix of devices. High research and development costs are also expected to dent margins. However, Qualcomm is well-positioned to benefit from solid 5G traction with greater visibility and a diversified revenue stream. The buyout of Veoneer is likely to further augment its automotive business.
It is focusing on the seamless transition from a wireless communications firm for the mobile industry to a connected processor company for the intelligent edge. It is also witnessing healthy traction in EDGE networking that helps to transform connectivity across diverse IoT devices.
Other noteworthy reports we are featuring today Booking Holdings Inc. and Chubb Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Amazon.com, Novo Nordisk, Qualcomm, Booking Holdings and Chubb
For Immediate Release
Chicago, IL – March 23, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Novo Nordisk A/S (NVO - Free Report) , Qualcomm Inc. (QCOM - Free Report) , Booking Holdings Inc. (BKNG - Free Report) and Chubb Ltd. (CB - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Amazon, Novo Nordisk and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Novo Nordisk A/S and Qualcomm Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Amazon.com lagged the broader market (-38.7% vs. -11.2% for the S&P 500) and the Zacks Tech sector (-14%) over the past year, reflecting fears of an extended period of post-Covid retrenchment in the company's capacity both in the retail as well as cloud businesses. Further, softness in online shopping activities remains a negative for its online stores.
These near-term challenges notwithstanding, Amazon's AWS business remains well positioned for the eventual recovery in business cloud spending. Ultrafast delivery services and expanding content portfolio effectively guarantee that Amazon hangs onto its market share in this period of weakness. Strengthening relationships with third-party sellers was a positive. Robust advertising business contributed well.
Improving Alexa skills along with robust smart home products offerings were tailwinds. Amazon's strong global presence and solid momentum among the small and medium businesses remain positives.
(You can read the full research report on Amazon.com here >>>)
Novo Nordisk shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+34.7% vs. +2.9%). The company has one of the broadest diabetes portfolios in the industry. Ozempic and Rybelsus have been performing well in the market. Drug sales have been gaining and maintaining momentum.
Label expansion of the existing drugs is likely to further boost sales. Ozempic is off to a solid start since its launch and will drive growth for the company. The launch of Rybelsus also looks impressive.
The supply issues with Wegovy have been resolved. The company has been diversifying its efforts to develop new treatments, which is encouraging. The patent expiry on some of the products in Novo Nordisk's portfolio remains a woe.
(You can read the full research report on Novo Nordisk here >>>)
Qualcomm shares have underperformed the Zacks Wireless Equipment industry over the past year (-19.0% vs. -15.5%). The company has offered a muted outlook for the second quarter due to rapid deterioration in demand and high channel inventory amid a challenging macroeconomic environment and business uncertainty.
Qualcomm expects softness in the handset market and weaker overall mix of devices. High research and development costs are also expected to dent margins. However, Qualcomm is well-positioned to benefit from solid 5G traction with greater visibility and a diversified revenue stream. The buyout of Veoneer is likely to further augment its automotive business.
It is focusing on the seamless transition from a wireless communications firm for the mobile industry to a connected processor company for the intelligent edge. It is also witnessing healthy traction in EDGE networking that helps to transform connectivity across diverse IoT devices.
(You can read the full research report on QUALCOMM here >>>)
Other noteworthy reports we are featuring today Booking Holdings Inc. and Chubb Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.